ArticleMaterials today. Bio2026
Supramolecularly gated enzymes: On-demand activity switching via host-guest competition for precision tumor therapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dynamic control over enzyme function has been of great interest in the field of enzyme engineering and disease treatment, however, achieving on-demand regulation of native enzymes in living systems remains challenging due to the complexity of cellular environments and the lack of selective interactions. Here, we introduce a novel enzyme activity regulation system based on supramolecular host-guest recognition that enables reversible and on-demand regulation of native enzyme activity in living cells without covalent modification. This system utilizes the high-affinity interaction between cucurbit[7]uril (CB[7]) and amantadine (Ad) to precisely control enzyme function. CB[7] binds to key residues on the enzyme surface, blocking the active site and switching off enzyme activity. Upon intracellular administration of Ad, CB[7] is competitively removed, restoring enzyme activity and allowing for dynamic regulation of cellular functions. This strategy was successfully validated with model enzymes, including catalase (CAT) and β-galactosidase (β-Gal), demonstrating its broad applicability. Furthermore, we extended this approach to enzyme/prodrug therapy, achieving localized prodrug activation and targeted cell death while minimizing off-target effects and systemic toxicity. Thus, this non-covalent, reversible regulation of enzyme activity represents a significant advancement over traditional methods, offering a versatile and biocompatible tool for studying protein function and developing targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.